New ETF Book by Larry Connors - Click here to read more
(Photo: http://www.newscom.com/cgi-bin/prnh/20091001/CG85941)
In addition to performing free heart health screenings in Central Park, veterinarians and veterinary cardiologists will provide information at the Canine Heart Health booth at the "Meet the Breeds" event on October 17 and 18.
Heart disease in dogs is almost as common as it is in humans. About 11 percent of the nearly 75 million dogs in the United States have heart disease, and that figure increases to as many as 60 percent among dogs over age 5 and certain predisposed breeds. Yet, a national survey shows that more than half of dog owners are unaware that their dog may be at risk of heart failure.
"Early diagnosis and treatment of heart failure can significantly prolong and improve the quality of a dog's life," says Nigel Swift, board-certified veterinarian with Boehringer Ingelheim, sponsor of the Mobile Dog Heart Health Tour. "We look forward to reaching out to local dog owners to educate them about heart disease in dogs and their treatment options. By emphasizing the importance of annual veterinary examinations and early diagnosis of heart disease, we hope to help more dogs live longer and better lives."
From 11 a.m. to 6 p.m. on October 13 at Central Park's Naumburg Bandshell, a local veterinary cardiologist will perform free dog heart screenings from inside a special soundproof mobile exam room. He will use a stethoscope to listen for heart murmurs and other irregular sounds as well as generally assess whether the dog shows any signs of heart disease.
The veterinarians on tour will also make sure that dog owners are aware of some of the common symptoms seen with heart disease: reduced willingness to walk, play or exercise; difficulty breathing; coughing; and loss of appetite. Dog owners can learn even more at www.yourdogsheart.com or by visiting the Canine Heart Health Booth at Meet the Breeds, being held at the Jacob Javits Convention Center from 10 a.m. to 5 p.m. October 17 and 18. Heart health screenings will not be conducted at this event, but veterinarians will be on hand to answer questions.
About Meet the Breeds
Hosted by the American Kennel Club and the Cat Fanciers' Association, this event is the world's largest showcase of dogs and cats, featuring 160 dog breeds and 41 cat breeds, demonstrations, shopping and children's events. Attendees may literally "meet the breeds" by petting the dogs, cats, puppies and kittens and learning about them directly from the experts.
Meet the Breeds will be held October 17 and 18 from 10 a.m. to 5 p.m. at the Jacob Javits Convention Center, 655 W. 34th Street in New York. To purchase discounted, pre-event tickets, visit http://www.akc.org/meet_the_breeds/. Tickets purchased online before Saturday, October 17, are $10 for adults and $6 for children 12 and under. As of October 17, tickets may be purchased online or at the door, when prices are $12 for adults and $8 for children.
About Congestive Heart Failure in Dogs
The Mobile Dog Heart Health Tour was organized to teach people about congestive heart failure (CHF) in dogs. CHF leads to excessive water and salt retention, causing fluid buildup in the lungs. Heart disease affects more than 60 percent of aged dogs, and while there is no cure for CHF, clinical study results have shown that dogs with the condition can live longer, better quality lives with early diagnosis and appropriate treatment.
About BI
Boehringer Ingelheim is the exclusive U.S. manufacturer of Vetmedin. Boehringer Ingelheim Vetmedica, Inc. (St. Joseph, Mo.), is a subsidiary of Boehringer Ingelheim Corporation based in Ridgefield, Conn., and a member of the Boehringer Ingelheim group of companies.
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 135 affiliates in 47 countries and approximately 39,800 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
In 2007, Boehringer Ingelheim posted net sales of US $15.0 billion (10.9 billion euro) while spending approximately one-fifth of net sales from its largest business segment, prescription medicines, on research and development.
For more information, please visit www.bi-vetmedica.com.
SOURCE Boehringer Ingelheim
http://www.bi-vetmedica.com/
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
